Part 1 of this series revealed that there are gaps in the regulation of drug wholesalers. Prescription medications were and may still be sold as arbitrage. They can be stockpiled and warehoused to reduce supply and raise prices. The unbridled buying and selling of these medications has allowed for the infiltration of unfit, adulterated pharmaceuticals into regulated distribution chains. Part 2 focused on the implications of a substantial part of the FDA’s budget being financed by user fees paid by the pharmaceutical industry. This could explain why the amount of time that a medication is approved has been cut in...